A mutant γ-glutamyltransferase with improved transpeptidase activity

Despite their potential applicative interest as biologically active compounds and as flavor enhancers, \u3b3-glutamyl derivatives are commercially underexploited compounds. This is mainly due to the difficulties connected with their supply at a reasonable cost. As a consequence, enzymatic approaches to their preparation, based on the use of \u3b3-glutamyltransferases (GGTs), have been proposed1 to circumvent both the low-yielding extractive procedures from natural sources and the troublesome chemical synthesis, rendered uneconomical by the need of protection and deprotection steps. GGTs catalyze the transfer of a \u3b3-glutamyl moiety from a donor substrate (e.g. glutathione or glutamine) to the primary amino group of an acceptor compound in a so-called transpeptidation reaction through the formation of a \u3b3-glutamyl-enzyme intermediate. However, also the use of GGTs as biocatalysts is not free from drawbacks. In addition to the transpeptidase activity, GGTs show a non-negligible hydrolase activity towards both the donor substrate and the newly formed transpeptidation product, affording irreversibly glutamic acid.2 In our ongoing studies on bacterial GGTs, we found that the presence of the lid loop \u2013 a short amino acids sequence covering the active site in most of the known GGTs \u2013 not only affects substrate selection, but also modulates hydrolase/transpeptidase activities.3 Within the TailGluTran Project,4 aimed at the development of mutant GGTs with improved transpeptidase activity, is currently under investigation a mutant enzyme obtained by inserting the sequence of the lid loop on the structure of a GGT naturally lacking it. The mutant enzyme shows promising high transpeptidase activity with respect to wild type counterparts and represents a starting point for further modifications in the search of a suitable biocatalyst intended for preparative purposes

Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells

Previous studies have shown that angiotensin II stimulates the synthesis of plasminogen activator inhibitor-1 in cultured vascular cells, which suggests that activation of the renin-angiotensin system may impair fibrinolysis. We have investigated the effects of angiotensin II and of valsartan, a recently developed angiotensin II antagonist that is highly specific and selective for the angiotensin II subtype 1 receptor, on plasminogen activator inhibitor-1 secretion by smooth muscle cells isolated from rat and human vessels. Angiotensin II induced a time- and concentration-dependent increase of plasminogen activator inhibitor activity in supernatants of rat aortic cells, which reached a plateau after 6 hours of incubation with 100 nmol/L angiotensin II (2.4+/-0.6-fold over control value; P:<0.001). The angiotensin II-induced plasminogen activator inhibitor activity was inhibited, in a concentration-dependent manner, by valsartan with an IC(50) value of 21 nmol/L. Valsartan fully prevented the angiotensin II-induced increase in plasminogen activator inhibitor-1 protein and mRNA. Furthermore, angiotensin II doubled the secretion of plasminogen activator inhibitor-1 by smooth muscle cells obtained from human umbilical and internal mammary arteries, and valsartan fully prevented it. Angiotensin II did not affect the secretion of tissue plasminogen activator antigen by any of the cell systems tested. Thus, valsartan effectively inhibits angiotensin II-induced plasminogen activator inhibitor-1 secretion without affecting that of tissue plasminogen activator in arterial rat and human smooth muscle cells

Acute-phase proteins before cerebral ischemia in stroke-prone rats : identification by proteomic

BACKGROUND AND PURPOSE: A high degree of proteinuria has been reported in stroke-prone spontaneously hypertensive rats (SHRSP). We studied the effect of salt loading on the detailed protein pattern of serum and urine in 3 rat strains: Wistar-Kyoto, spontaneously hypertensive rats, and SHRSP, an inbred animal model for a complex form of cerebrovascular disorder resembling the human disease. METHODS: Rats were given a permissive diet and received 1% NaCl in drinking water. The protein pattern in body fluids was assessed over time by 2-dimensional electrophoretic analysis. Brain alterations were monitored by MRI and histology. RESULTS: Several proteins were excreted in urine after weeks of treatment and in advance of stroke: transferrin, hemopexin, albumin, alpha(2)-HS-glycoprotein, kallikrein-binding protein, alpha(1)-antitrypsin, Gc-globulin, and transthyretin. Markers of an inflammatory response, including very high levels of thiostatin, were detected in the serum of SHRSP at least 4 weeks before a stroke occurred. CONCLUSIONS: In SHRSP subjected to salt loading, an atypical inflammatory condition and widespread alterations of vascular permeability developed before the appearance of anomalous features in the brain detected by MRI. Urinary concentrations of each of the excreted serum proteins correlated positively with time before stroke occurred

Magnesium inhibits arterial thrombi after vascular injury in rat: in vivo impairment of coagulation

Magnesium deficiency is associated with a high frequency of cardiac arrhythmia, hypertension and sudden ischemic death. We investigated the if vivo effects of intravenous magnesium administration in a rat model of chemically induced (FeCl3) carotid thrombosis. The infusion of magnesium sulfate (MgSO4) before the topical application of FeCl5 prevented thrombus formation at concentrations of 0.3 M and 0.6 M, and delayed it even at 0.15 M. Similar results were obtained with MgCl2. The infusion of MgSO4 0.6 M seven minutes after FeCl3 application delayed but did not prevent thrombus formation. MgSO4 slightly reduced platelet aggregation ex vivo without affecting plasma clotting tests, but in vivo blood clotting time was markedly prolonged (tail transection method), thus indicating profoundly impaired coagulation. These data provide a rationale for the use of magnesium as an antithrombotic agent. but its pharmacological effect critically depends on the timing of administration

Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke

We evaluated the expression of two extra-cellular protease systems in a model of spontaneous cerebrovascular pathology: spontaneously hypertensive stroke-prone rats (SHRSP). The appearance of brain damage in individual animals was imaged and followed by means of magnetic resonance imaging (MRI). In situ zymography of brain slices obtained 3 days after the appearance of brain damage showed an increase in plasminogen activator (PA)/plasmin activity that co-localised with the cerebral damage detected by MRI; there was also concomitant accumulation/activation of inflammatory cells in the damaged area. Proteolytic activity was inhibited by the urokinase-specific inhibitor amiloride but not by an antibody against tissue-type plasminogen activator (t-PA). SDS-PAGE zymography of brain extracts revealed the presence of 58 kDa plasminogen-dependent lysis areas in the ischemic and non-ischemic tissues, and a 33 kDa lysis area in ischemic tissue only. An antibody against t-PA inhibited the former, whereas the latter was inhibited by amiloride. The specific induction of urokinase-type plasminogen activator (u-PA) in the damaged tissue was further confirmed by the fact that both u-PA protein mass and mRNA were markedly increased in the damaged cerebral areas. Concomitant metalloproteinase-2 (MMP-2) activation was only observed in the damaged area. These data suggest that u-PA is expressed and selectively catalyses proteolysis in the injured area of spontaneous brain damage in SHRSP

Immobilization of &#947;-glutamyl transpeptidase from equine kidney for the synthesis of kokumi peptides

Kokumi is a Japanese term that refers to taste perception defined as having mouthfulness, thickness and a long-lasting savory sensation. Although being nearly tasteless in themselves, kokumi compounds are able to elicit strong taste sensations, especially when associated with protein-rich food, thus acting as true flavor enhancers. Kokumi compounds in nature are mainly \u3b3-glutamyl derivatives of amino acids or modified amino acids [1]. Despite their relatively simple chemical structure, the synthesis of \u3b3-glutamyl derivatives through the classical peptide chemistry is not straightforward due to the need of protection and deprotection steps. Therefore, an enzymatic approach can represent an appealing solution for their supply. \u3b3-Glutamyl transpeptidase (GGT, E.C. 2.3.2.2) is a an intrinsic membrane enzyme which transfers the \u3b3-glutamyl moiety of glutathione to acceptors producing \u3b3-glutamyl derivatives [2,3]. In this context, an immobilization study of the GGT from equine kidney (ekGGT) [4] was performed with the aim to develop a robust biocatalyst for the synthesis of \u3b3-glutamyl derivatives of industrial relevance. Different binding chemistry and chemical activation of the support as well as reaction conditions were assayed to set up a tailor-made immobilization protocol. Octyl/glyoxyl heterofunctional agarose [5] resulted in a high immobilization yield and a good activity recovery